GSK plc
http://www.gsk.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From GSK plc
Amid Growing Pandemic Fears, Moderna Gets BARDA Funding For Flu Program
The biotech got a $176m award for its pandemic influenza vaccine program through BARDA’s Rapid Response Partnership Vehicle.
Stock Watch: New Vaccine Battlegrounds
Three new vaccines to prevent RSV infections in seniors and sales trends in pediatric vaccines highlight a shift away from childhood vaccines and a possible age-related immunity deficit.
Moderna And GSK Hit By Declining RSV Vaccines Expectations
The efficacy of Moderna’s jab appears to fade faster than its rivals, while experts were surprised by an FDA panel’s recommendation to narrow the use of all three RSV vaccines.
Victory For Verona As FDA Approves Potential COPD Blockbuster
The respiratory specialist is set to hit the ground running with Ohtuvayre, the first COPD inhaled product with a novel mechanism of action to be approved in over two decades.
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
- Other Names / Subsidiaries
-
- ABR Development
- Affinivax, Inc.
- Cellzome
- Corixa Corporation
- Fountain Acquisition Corporation
- Genelabs Technologies, Inc.
- GlycoVaxyn AG
- Human Genome Sciences, Inc.
- GlaxoSmithKline plc
- ID Biomedical Corporation
- Okairos AG
- PRAECIS Pharmaceuticals, Inc.
- Reliant Pharmaceuticals
- Sierra Oncology, Inc.
- Sirtris Pharmaceuticals
- Sitari Pharmaceuticals, Inc.
- SmithKline Beecham
- Stiefel Laboratories, Inc.
- Tesaro, Inc.
- ViiV Healthcare
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice